Nuro, Inc.

NURO operates across neurotechnology, medical applications, neuroscience, and human-computer interaction. Its stated focus is non-surgical systems that interpret neurological signals for communication and digital-device control, with products also described for neurological monitoring and mental-state measurement. This places its offering at the intersection of assistive communication and brain-computer interfaces rather than in conventional consumer software or implant-based medical devices. The product range includes NUOS 3, KOMPOS, GRIDLY, MENTIS, and PAD, spanning communication interfaces, software control, and monitoring. NURO’s June 2025 GRIDLY announcement emphasized wireless control of both Microsoft and Apple software without implants, while its Spinex Medical distribution agreement points to a healthcare-provider channel in the United States. The company is listed in biotechnology, health care, medical, neuroscience, and human-computer interaction categories and has a recorded total of $722,801 across eight funding rounds, most of them early-stage or grant financing.

NURO was founded in 2017 and has developed a portfolio spanning non-surgical communication, device control, and neurological monitoring. Its recorded funding history begins with a $30,088 pre-seed round in 2016 and includes subsequent pre-seed, seed, and grant rounds through a $39,249 grant on Feb 8, 2021. The eight listed rounds total $722,801, indicating a modest disclosed financing base; no later round is included in the company’s funding history. A personnel milestone followed on May 1, 2024, when Iram Hasan joined as CTO. In June 2025, the company announced a U.S. distribution partnership with Spinex Medical and launched GRIDLY, extending its product activity toward distribution and software-control use cases. GRIDLY’s stated compatibility with Microsoft and Apple software marks a concrete product milestone beyond the company’s broader platform descriptions. The sequence suggests a shift from early development and grant-backed financing toward commercialization through named products and a distributor relationship.